Press Releases :: IceCure Medical Ltd. (ICCM)

Skip to main content Skip to section navigation Skip to footer

Sep 04, 2024 8:30 am EDT

IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences

Aug 28, 2024 8:30 am EDT

USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies

Aug 20, 2024 8:30 am EDT

IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets

Aug 14, 2024 8:30 am EDT

IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery

Aug 13, 2024 8:30 am EDT

IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024

Aug 07, 2024 8:30 am EDT

IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials"

Jul 22, 2024 8:30 am EDT

99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society

Jul 19, 2024 4:30 pm EDT

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

Jul 09, 2024 8:30 am EDT

European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer

Jul 01, 2024 8:30 am EDT

U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes

Select a page:

rss_feed News RSS

IceCure Medical HQ: 7 Ha’Eshel St., PO Box 3163, Caesarea, 3079504, Israel

© 2025 All Rights Reserved IceCure Medical

Branding by

Terms of Use | Privacy | Last Updated: April 9, 2023